Posters and Publications
This page is intended to provide scientific information to research and healthcare professionals. Evofem Biosciences’ first commercial product was recently approved by the Food and Drug Administration. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. EVO100 has not been approved by the Food and Drug Administration or any other regulatory agency.
Evofem assumes no responsibility for the accuracy of any information or data contained on any third party website. Evofem has not independently verified the accuracy of such information or data, and there can be no assurance as to the accuracy of any such information or data. Links to this information and data are provided for informational purposes only.